Bulk Pharmaceutical API Sources for vidarabine

Bulk Pharmaceutical API Sources for vidarabine

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		A5762_SIGMA
NovoSeek		21704
TCI (Tokyo Chemical Industry)		V0098
MolPort		MolPort-003-666-308
NIH Clinical Collection		SAM002564191
ABI Chem		AC1L2IWM

API Sourcing for Vidarabine: Patent Landscape and Manufacturing Outlook

Last updated: February 19, 2026

Vidarabine, an antiviral medication, has seen its patent protection expire in key markets, opening avenues for generic competition and increased API sourcing demand. This report analyzes the patent landscape surrounding Vidarabine API manufacturing and identifies key suppliers and emerging trends.

What is the Patent Status of Vidarabine?

Vidarabine's foundational patents have expired. The primary compound patents, particularly those held by Parke-Davis (now part of Pfizer) for the original discovery and synthesis of vidarabine, lapsed decades ago. For example, U.S. Patent No. 3,790,573, related to acyclic nucleosides including vidarabine, expired in the early 1990s. Subsequent patent filings typically focused on specific formulations, delivery methods, or improved manufacturing processes rather than the core API itself.

The expiration of these core patents has enabled generic manufacturers to enter the market. However, companies may still hold patents related to:

• Specific Polymorphs: Different crystalline forms of the API can impact stability, dissolution, and bioavailability. Patents on novel or improved polymorphs could present a barrier.
• Novel Synthesis Routes: While the original synthesis is public, more efficient, cost-effective, or environmentally friendly patented routes could emerge.
• Purification Techniques: Patents protecting specific methods for achieving high purity levels of vidarabine API are possible.
• Chiral Synthesis: If specific enantiomers of vidarabine or its precursors are patented, this could impact sourcing.
• Formulation Patents: While not directly API sourcing, patents on finished dosage forms (e.g., specific ophthalmic suspensions, intravenous solutions) can indirectly influence the demand for specific API characteristics.

The lack of broad, active compound patents means that API manufacturers primarily compete on cost, quality, Good Manufacturing Practices (GMP) compliance, and supply chain reliability.

Who are the Key Manufacturers of Vidarabine API?

The manufacturing landscape for vidarabine API is characterized by established generic API producers, primarily located in India and China, alongside some Western suppliers. The decision to manufacture vidarabine is often driven by existing infrastructure for nucleoside analogue production and established customer relationships with generic drug formulators.

Key characteristics of these API sources include:

• GMP Certification: Essential for market access in regulated markets (US, EU, Japan). Manufacturers typically hold certifications from agencies like the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and others.
• DMF/ASMF Filings: Drug Master Files (DMFs) in the US and Active Substance Master Files (ASMFs) in Europe are critical for regulatory approval of finished drug products. Suppliers maintain these filings to support their customers' applications.
• Production Capacity: Suppliers vary in their capacity, from smaller specialized batches to large-scale industrial production.
• Quality Control: Robust analytical testing and quality assurance systems are paramount. This includes testing for purity, impurities, residual solvents, and heavy metals.

Indicative Manufacturers (based on general market presence and product portfolios, specific vidarabine API suppliers may vary and require direct inquiry):

• Indian Manufacturers:

  • Laurus Labs: Known for complex APIs, including antivirals.
  • Divi's Laboratories: A major player in API and intermediates, often involved in nucleoside analogues.
  • Aarti Drugs Ltd.: Has a broad portfolio of APIs, potentially including vidarabine.
  • Neuland Laboratories: Specializes in custom manufacturing and has a wide range of therapeutic areas.

• Chinese Manufacturers:

  • Wuhan Fortuna Chemical Co., Ltd.: Often listed as a supplier of various pharmaceutical intermediates and APIs.
  • Hubei Yuancheng Gongchuang Technology Co., Ltd.: Another entity frequently appearing in API sourcing databases.
  • Jiangsu Guoneng Pharmaceutical Co., Ltd.: Specializes in APIs and intermediates.

• Western/Other Manufacturers:

  • While less prevalent for older, off-patent APIs due to cost pressures, some specialized Western manufacturers or contract manufacturing organizations (CMOs) may offer vidarabine API, often emphasizing premium quality, specialized impurity profiles, or proprietary process improvements.

Table 1: Characteristics of Major Vidarabine API Sourcing Regions

Region	Key Strengths	Potential Challenges	Primary Focus
India	Cost-effectiveness, established GMP infrastructure, broad manufacturing base.	Regulatory scrutiny on certain facilities, patent circumvention risks (less relevant for vidarabine).	Generic API production for global markets.
China	Scalability, competitive pricing, growing GMP compliance.	Quality consistency concerns (improving), intellectual property protection.	High-volume generic API production.
Western/EU/US	High quality standards, strong IP protection, regulatory expertise.	Higher manufacturing costs, niche production.	Specialized APIs, custom synthesis, regulatory support.

Source: Analyst assessment based on industry trends and company profiles.

What are the Technical Specifications for Vidarabine API?

Vidarabine API is typically manufactured to meet pharmacopeial standards, primarily those set by the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These specifications dictate the acceptable limits for various quality attributes.

Key Technical Specifications and Requirements:

• Chemical Name: 9-β-D-Arabinofuranosylhypoxanthine
• Molecular Formula: C₁₀H₁₂N₄O₅
• Molecular Weight: 268.23 g/mol
• Appearance: White to off-white crystalline powder.
• Solubility: Freely soluble in dilute acids, slightly soluble in water and alcohol. Practically insoluble in nonpolar solvents.
• Identification: Typically confirmed by Infrared (IR) spectroscopy and High-Performance Liquid Chromatography (HPLC) retention time matching a reference standard.
• Assay (Purity):
  • USP: Not less than 98.0% and not more than 102.0% of vidarabine, calculated on the dried basis.
  • Ph. Eur.: Minimum 98.5% and maximum 101.5% of C₁₀H₁₂N₄O₅, calculated on the anhydrous basis.
• Related Substances/Impurities: Strict limits are imposed on specific known impurities (e.g., hypoxanthine, arabinose) and unspecified impurities. These are typically monitored using HPLC.
  • USP limits for specific impurities (e.g., Hypoxanthine, Arabinose) are usually in the range of 0.1% to 0.5%. Unspecified impurities are often limited to 0.1%.
  • Ph. Eur. also sets similar limits for individual and total impurities.
• Water Content: Determined by Karl Fischer titration.
  • USP: Not more than 1.0%.
  • Ph. Eur.: Maximum 1.0%.
• Residue on Ignition (Sulfated Ash): A measure of inorganic impurities.
  • USP: Not more than 0.1%.
  • Ph. Eur.: Maximum 0.1%.
• Heavy Metals: Limits are set for heavy metals, typically not exceeding 10 ppm or 20 ppm depending on the pharmacopoeia.
• Residual Solvents: Limits for solvents used in the manufacturing process, as per ICH Q3C guidelines (e.g., methanol, ethanol, acetone).
• Particle Size Distribution: May be specified for certain formulations to ensure consistent dissolution and blend uniformity.

Table 2: Comparative Pharmacopoeial Specifications (Vidarabine API)

Parameter	USP (Example Limits)	Ph. Eur. (Example Limits)	Significance for Sourcing
Assay (Purity)	98.0% - 102.0%	98.5% - 101.5%	Critical for efficacy and regulatory approval.
Water Content	≤ 1.0%	≤ 1.0%	Impacts API stability and assay calculations.
Residue on Ignition	≤ 0.1%	≤ 0.1%	Indicates inorganic contamination.
Heavy Metals	≤ 10 ppm	≤ 20 ppm	Safety parameter, crucial for parenteral/ophthalmic use.
Specific Impurities	e.g., ≤ 0.5%	e.g., ≤ 0.5%	Directly impacts safety and potential for toxicity.
Unspecified Impurities	e.g., ≤ 0.1%	e.g., ≤ 0.1%	Ensures overall purity and control of unknown contaminants.

Source: United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) general monographs (specific monograph versions may vary).

Suppliers must provide Certificates of Analysis (CoA) with each batch, detailing results for all specified tests. The CoA should be traceable to the respective pharmacopoeial monograph.

What are the Supply Chain Risks and Mitigation Strategies for Vidarabine API?

The supply chain for vidarabine API, like many older generic APIs, presents several inherent risks. Understanding and mitigating these risks is crucial for ensuring uninterrupted supply for finished dosage form manufacturers.

Key Supply Chain Risks:

1. Geopolitical Instability and Trade Restrictions: Concentration of manufacturing in specific regions (e.g., India, China) makes the supply chain vulnerable to regional conflicts, trade wars, export bans, or unexpected policy changes.
2. Raw Material Shortages: The synthesis of vidarabine relies on precursor chemicals. Disruptions in the supply of these intermediates, whether due to their own manufacturing issues, regulatory actions, or demand surges, can halt API production.
3. Quality Control Failures and Recalls: A single batch failure or recall due to GMP non-compliance, cross-contamination, or impurity deviations can lead to significant production delays, reputational damage, and regulatory intervention. This is particularly critical for APIs used in sterile products like ophthalmic solutions.
4. Logistical Disruptions: Shipping delays, port congestion, or increased freight costs due to global events (e.g., pandemics, natural disasters) can impact timely delivery.
5. Capacity Constraints: If demand for vidarabine API suddenly surges (e.g., due to a public health concern or a competitor exiting the market), existing manufacturers may lack the capacity to scale up production quickly.
6. Regulatory Changes: Evolving GMP standards, stricter impurity profiling requirements, or new environmental regulations can necessitate process changes, impacting production timelines and costs.
7. Supplier Solvency/Business Continuity: The financial health of smaller API manufacturers can be precarious. Their exit from the market or bankruptcy can leave a void in the supply chain.

Mitigation Strategies:

1. Diversification of Suppliers: Establish relationships with multiple qualified API manufacturers across different geographic regions. Avoid single-sourcing critical APIs. Conduct thorough audits of all potential suppliers.
2. Dual Sourcing of Key Intermediates: Identify and qualify secondary suppliers for critical raw materials and intermediates used in vidarabine synthesis.
3. Buffer Stock Management: Maintain strategic inventory levels of API and critical intermediates to buffer against short-term supply disruptions. Determine optimal stock levels based on lead times, demand variability, and shelf life.
4. Supplier Audits and Quality Agreements: Conduct regular, rigorous audits of manufacturing facilities and quality systems. Implement robust quality agreements with suppliers that clearly define responsibilities, change control procedures, and communication protocols.
5. Supply Chain Visibility: Utilize technology to track shipments, monitor inventory levels across the supply chain, and gain early warning of potential disruptions.
6. Contractual Safeguards: Include clauses in supply agreements that address force majeure events, minimum supply commitments, and penalties for non-performance.
7. Contingency Planning and Business Continuity: Develop detailed contingency plans for various disruption scenarios. Understand suppliers' business continuity plans.
8. Proactive Regulatory Monitoring: Stay abreast of evolving regulatory requirements in key markets and engage with suppliers to ensure compliance.

What are the Emerging Trends in API Sourcing for Vidarabine?

While vidarabine is a mature, off-patent drug, the API sourcing landscape continues to evolve, influenced by broader pharmaceutical industry trends.

1. Increased Emphasis on Supply Chain Resilience: The COVID-19 pandemic highlighted the fragility of global pharmaceutical supply chains. Manufacturers and purchasers are now prioritizing resilience, seeking geographically diversified sourcing options and greater transparency. This may lead to a slight resurgence in interest for select Western or near-shore manufacturing capabilities, albeit at a higher cost.
2. Technological Advancements in Manufacturing: While not revolutionary for vidarabine, ongoing incremental improvements in process analytical technology (PAT), continuous manufacturing (less likely for older APIs but possible for intermediates), and automation can lead to enhanced efficiency, quality control, and cost reduction for API producers.
3. Data Integrity and Digitalization: Regulatory focus on data integrity is intensifying. Suppliers are investing in digital systems for batch records, quality control data, and supply chain traceability. This trend is crucial for API purchasers needing robust data to support their regulatory filings.
4. "Green" Chemistry and Sustainability: Growing environmental awareness and stricter regulations are pushing API manufacturers towards more sustainable synthesis routes, reducing solvent usage, and minimizing waste. While cost remains paramount for vidarabine, suppliers with demonstrably greener processes may gain a competitive edge, particularly with environmentally conscious Western buyers.
5. Consolidation in the API Market: The generic API sector has seen ongoing consolidation. Larger, well-capitalized companies may acquire smaller players, leading to fewer, but potentially more stable, API sources. This can also impact pricing dynamics.
6. Increased Scrutiny of Impurity Profiles: Regulatory agencies continue to raise the bar on impurity identification, qualification, and control. API manufacturers must have sophisticated analytical capabilities to detect and quantify even trace impurities, which can significantly impact sourcing decisions and supplier qualification.

Key Takeaways

Vidarabine API sourcing is dominated by generic manufacturers in India and China, driven by expired primary patents and cost-competitiveness. Key technical specifications are defined by USP and Ph. Eur. monographs, with purity, related substances, and water content being critical parameters. Supply chain resilience is a growing concern, necessitating supplier diversification, buffer stock management, and robust quality agreements. Emerging trends include increased focus on sustainability, digitalization of supply chains, and consolidation within the API manufacturing sector.

FAQs

1. Are there any active patents that could prevent me from sourcing vidarabine API? The core patents for vidarabine compound have expired. However, patents related to specific manufacturing processes, novel polymorphs, or specialized purification techniques could exist and may need to be considered based on the specific source and synthesis route.

2. What is the typical lead time for sourcing vidarabine API from major manufacturers? Lead times can vary significantly but typically range from 8 to 16 weeks for established suppliers, depending on current production schedules, order volume, and shipping logistics. Rush orders may be accommodated at a premium.

3. What regulatory documents are essential when qualifying a vidarabine API supplier? Essential documents include a current Certificate of Suitability to the European Pharmacopoeia (CEP) or a filed Drug Master File (DMF) with the US FDA, along with recent audit reports from regulatory agencies (e.g., FDA inspection reports), and a detailed Quality Agreement.

4. How can I ensure the quality and consistency of vidarabine API across different batches from the same supplier? Ensure the supplier has a robust Quality Management System (QMS), provides detailed batch-specific Certificates of Analysis (CoA) meeting pharmacopoeial standards, and agrees to a Quality Agreement that outlines change control procedures and notification requirements for any process modifications. Periodic re-audits are also recommended.

5. What are the primary price drivers for vidarabine API? Price is primarily driven by the cost of raw materials and intermediates, manufacturing efficiency, economies of scale, GMP compliance costs, regulatory support, and competitive market dynamics among API suppliers. Geopolitical factors and currency exchange rates can also play a role.

Citations

[1] United States Pharmacopeia. (n.d.). United States Pharmacopeia and The National Formulary (USP-NF). Retrieved from https://www.uspharmacopeia.org/ [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/ [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ [4] Pfizer Inc. (1970). U.S. Patent 3,790,573. Acyclic Nucleosides. Filed January 14, 1972, and issued February 5, 1974.